Scholar Rock Holding Corporation
SRRK
$52.52
-$0.54-1.02%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
11/12/2025
-
MarketBeat
8/14/2026
-
Business Wire
8/13/2026
-
Simply Wall St
8/13/2026
-
MarketBeat
8/13/2026
-
TipRanks
8/13/2026
-
TipRanks
8/13/2026
-
Tickeron - Stocks
8/13/2026
-
TipRanks
8/12/2026
-
Tickeron - Stocks
8/11/2026
-
MarketBeat
8/11/2026
-
MarketBeat
8/10/2026
-
Simply Wall St
8/10/2026
-
TipRanks
8/8/2026
-
Tickeron - Stocks
8/8/2026
-
Tickeron - Stocks
8/8/2026
-
Tickeron - Stocks
8/7/2026
-
TipRanks
8/7/2026
-
TipRanks
8/7/2026
-
The Cerbat Gem
8/7/2026
-
MarketBeat
8/7/2026
-
Tickeron - Stocks
Scholar Rock Holding (SRRK, $52.64) price may drop as it broke higher Bollinger Band on Aug 06, 2026
8/7/2026
-
Tickeron - Stocks
8/7/2026
-
The Cerbat Gem
8/7/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 6, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 9 and 13 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 259 3860
Address
301 Binney Street
3rd Floor
Cambridge, MA 02142
3rd Floor
Cambridge, MA 02142
Country
Year Founded
Business Description
Sector
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating...
more